SCHEMBL3087968

SCHEMBL3087968

CCN(CC)C(=O)c1nc(N)nc2ccc(Br)cc12

nearest known ligand 0.50

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HSP90AA1 P07900 1/20 0.47
ALDH1A1 P00352 8/20 0.43
GAA P10253 3/20 0.43
HPGD P15428 2/20 0.43
KDM4E B2RXH2 1/20 0.43
HTT P42858 1/20 0.42
SMN1; SMN2 Q16637 2/20 0.41
ADORA3 P0DMS8 1/20 0.41
USP2 O75604 1/20 0.41
LMNA P02545 2/20 0.41
NPC1 O15118 1/20 0.40
TP53 P04637 1/20 0.40
MAPK1 P28482 1/20 0.40
RAB9A P51151 1/20 0.40
ADORA2A P29274 1/20 0.40
RXFP1 Q9HBX9 2/20 0.40
CYP1A2 P05177 1/20 0.40
CYP2D6 P10635 1/20 0.40
CYP2C9 P11712 1/20 0.40
CYP2C19 P33261 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3088463 0.85 HSP90AA1 (0.53) HSP90AA1ALDH1A1HPGDKDM4EADORA3
SCHEMBL13144829 0.84 ALDH1A1 (0.41) HSP90AA1ALDH1A1HPGDSMN1; SMN2LMNA
SCHEMBL3088521 0.84 HSP90AB1 (0.45) ALDH1A1HPGDKDM4ESMN1; SMN2LMNA
SCHEMBL3092345 0.84 ALDH1A1 (0.41) ALDH1A1HPGDKDM4EHTTSMN1; SMN2
SCHEMBL3097002 0.82 HSP90AA1 (0.48) HSP90AA1ALDH1A1GAAHPGDKDM4E
SCHEMBL16628707 0.82 TLR8 (0.39) HSP90AA1ALDH1A1HPGDLMNADHFR
SCHEMBL3089581 0.82 HPGD (0.50) HSP90AA1ALDH1A1GAAHPGDSMN1; SMN2
SCHEMBL3099210 0.81 ADORA3 (0.54) HSP90AA1ALDH1A1HPGDKDM4EADORA3
SCHEMBL16628739 0.79 IP6K1 (0.44) HSP90AA1ALDH1A1GAAHPGDKDM4E
SCHEMBL3099560 0.79 CYP3A4 (0.48) ALDH1A1HPGDHTTSMN1; SMN2LMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2164833-B1 Quinazolinamide derivatives useful for the treatment of tumour diseases MERCK PATENT GMBH (DE) 2015-04-15 EP claimed
US-8501754-B2 Quinazolinamide derivatives MERCK PATENT GMBH (DE) 2013-08-06 US claimed
US-20100234324-A1 Quinazolinamide derivatives MERCK PATENT GESELLSCHAFT MIT BESCHRANKTER HAFTUNG (DE) 2010-09-16 US claimed
EP-2164833-B1 Quinazolinamide derivatives useful for the treatment of tumour diseases MERCK PATENT GMBH (DE) 2015-04-15 EP disclosed
US-8501754-B2 Quinazolinamide derivatives MERCK PATENT GMBH (DE) 2013-08-06 US disclosed
US-20100234324-A1 Quinazolinamide derivatives MERCK PATENT GESELLSCHAFT MIT BESCHRANKTER HAFTUNG (DE) 2010-09-16 US disclosed
EP-2164833-A2 QUINAZOLINAMIDE DERIVATIVES Merck Patent GmbH (DE) 2010-03-24 EP disclosed
WO-2009010139-A2 QUINAZOLINAMIDE DERIVATIVES MERCK PATENT GMBH (DE) 2009-01-22 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100234324-A1 Quinazolinamide derivatives HSP90AB1, HSP90AA1, HSP90AB2P HSP90AA1 2/4885ALDH1A1 1776/4885GAA 1465/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.